Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | LTA4H | P09960 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL795951 | 0.82 | L3MBTL1 (0.35) | FDPSTSHRHDAC1HDAC6LTA4H | |
| SCHEMBL3653051 | 0.77 | USP2 (0.32) | FDPSTSHRHDAC1HDAC6LTA4H | |
| SCHEMBL2429098 | 0.70 | CYP1A2 (0.41) | FDPSALOX15TSHRMAPTHDAC1 | |
| SCHEMBL27491044 | 0.68 | HAVCR2 (0.37) | FDPSALOX15TSHRKDM4EMAPT | |
| SCHEMBL3014789 | 0.68 | LMNA (0.40) | TSHRKDM4ELTA4H | |
| SCHEMBL3021750 | 0.67 | FDPS (0.40) | FDPSALOX15TSHRHDAC1HDAC6 | |
| SCHEMBL5828209 | 0.67 | FDPS (0.40) | FDPSTSHRHDAC1HDAC6LTA4H | |
| SCHEMBL4551626 | 0.67 | MEN1 (0.39) | FDPSTSHRHDAC1HDAC6LTA4H | |
| SCHEMBL4409381 | 0.67 | NPC1 (0.41) | FDPSTSHRKDM4EMAPTLTA4H | |
| SCHEMBL28251675 | 0.67 | CYP1A2 (0.42) | ALOX15TSHRKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130231307-A1 | NOVEL ANTIVIRAL ACYCLIC NUCLEOSIDE PHOSPHONATES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2013-09-05 | — | — | US | disclosed |
| EP-2616474-A1 | NOVEL ANTIVIRAL ACYCLIC NUCLEOSIDE PHOSPHONATES | Centre National De La Recherche Scientifique (FR) | 2013-07-24 | — | — | EP | disclosed |
| WO-2012034719-A1 | NOVEL ANTIVIRAL ACYCLIC NUCLEOSIDE PHOSPHONATES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231307-A1 | NOVEL ANTIVIRAL ACYCLIC NUCLEOSIDE PHOSPHONATES | PNP, TYMP, EIF2AK2 | FDPS 1374/4885ALOX15 4519/4885TSHR 4113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.